TXNL1 and chronic obstructive pulmonary disease: The present study aimed to determine whether the key mechanism of COPD exacerbation of AS is pulmonary microvascular barrier dysfunction, whether lung inflammation triggers systemic inflammation, and whether TXL can enhance the antiatherosclerotic effect of Ato in COPD combined with AS through pulmonary microvascular barrier protection.